Arrowhead Pharmaceuticals (ARWR) EBT (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly EBT came in at -$137.6 million in Q1 2026, down 137.22% YoY from $369.6 million in Q1 2025, and down 586.59% on a QoQ basis from $28.3 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) EBT (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of EBT data on file, last reported at -$137.6 million in Q1 2026.
- Quarterly EBT fell 137.22% year-over-year to -$137.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$252.3 million (down 65.66% YoY) and the FY2025 annual result came in at $51.5 million, up 108.41% from the prior year.
- EBT slipped to -$137.6 million in Q1 2026, from $28.3 million in the prior quarter.
- In the past five years, EBT ranged from a high of $369.6 million in Q1 2025 to a low of -$179.1 million in Q2 2025.
- A 5-year average of -$58.0 million and a median of -$103.4 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT plunged 366.37% — and 2025, when it jumped 391.05%.
- Tracing ARWR's EBT over 5 years: stood at -$41.8 million in 2022, then slumped by 231.84% to -$138.7 million in 2023, then dropped by 26.26% to -$175.1 million in 2024, then jumped by 116.14% to $28.3 million in 2025, then tumbled by 586.59% to -$137.6 million in 2026.
- The last three EBT figures came in at -$137.6 million (Q1 2026), $28.3 million (Q4 2025), and $36.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -178.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -178.91 Mn |
| Mar 31, 2026 | -137.57 Mn |
| Dec 31, 2025 | 28.27 Mn |
| Sep 30, 2025 | 36.12 Mn |
| Jun 30, 2025 | -179.09 Mn |
| Mar 31, 2025 | 369.62 Mn |
| Dec 31, 2024 | -175.12 Mn |
| Sep 30, 2024 | -172.80 Mn |
| Jun 30, 2024 | -173.98 Mn |
| Mar 31, 2024 | -127.00 Mn |
| Dec 31, 2023 | -138.69 Mn |
| Sep 30, 2023 | -108.99 Mn |
| Jun 30, 2023 | -103.38 Mn |
| Mar 31, 2023 | 47.68 Mn |
| Dec 31, 2022 | -41.79 Mn |
| Sep 30, 2022 | -82.16 Mn |
| Jun 30, 2022 | -72.05 Mn |
| Mar 31, 2022 | 44.37 Mn |
| Dec 31, 2021 | -62.87 Mn |
| Sep 30, 2021 | -63.37 Mn |